NCT04015050

Brief Summary

A randomised, controlled, double-blind, parallel group, multi-country study to investigate the safety and tolerance of infant formula with prebiotics and postbiotics in healthy term infants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
279

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 4, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 10, 2019

Completed
Same day until next milestone

Study Start

First participant enrolled

July 10, 2019

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 3, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 3, 2021

Completed
Last Updated

December 17, 2021

Status Verified

December 1, 2021

Enrollment Period

2.4 years

First QC Date

July 4, 2019

Last Update Submit

December 16, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Weight gain

    from baseline until the age of 17 weeks (test product versus control product). Weight gain will be calculated as weight (in grams) at visit minus weight at baseline divided by the number of days.

    17 weeks

Study Arms (2)

Test product

EXPERIMENTAL

Cow's milk based infant formula containing prebiotics and postbiotics

Other: milk based infant formula

Control product

ACTIVE COMPARATOR

Cow's milk based infant formula without prebiotics and postbiotics

Other: milk based infant formula

Interventions

Cows milk ased infant formula

Control productTest product

Eligibility Criteria

Age0 Days - 17 Weeks
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • \. Healthy, singleton, term infants (gestational age ≥37 weeks + 0 days and ≤41weeks + 6 days);
  • \. Infants with age at screening ≤14 days;
  • \. Birth weight within 10th to 90th percentile per gestational age and sex, according to Intergrowth Standards;
  • \. Head circumference at screening within ±2 SD per age and sex according to WHO Child Growth Standards;
  • \. a Randomised groups: Infants who are exclusively formula fed and/or whose mothers have autonomously decided to exclusively formula feed, i.e. not to breastfeed or have ended breastfeeding before screening, and who are intending to exclusively formula feed at least till their infant is 17 weeks of age; OR b Breastfed reference group: Infants who are exclusively breastfed and whose mothers are intending to exclusively breastfeed at least till their infant is 17 weeks of age;
  • \. Written informed consent from parent(s) and/or legal guardian(s) aged ≥18 years at screening.

You may not qualify if:

  • \. Randomised groups: Infants who require a special diet other than non-hydrolysed, cow's milk based infant formula (e.g. due to known or suspected to have cow's milk allergy, soy allergy and/or lactose intolerance);
  • \. Infants with current or previous illnesses/conditions and/or known or suspected congenital diseases or malformations which could interfere with the study or its outcome parameters, such as but not limited to: GI malformations, congenital metabolic disorders, severe congenital cardiac disorders, immunodeficiency or major surgery, as per the clinical judgement of the Investigator;
  • \. Infants with previous, current or intended participation in any other clinical study involving investigational or marketed products;
  • \. Incapability of infants' parents to comply with study protocol as per the judgement of the Investigator;
  • \. Infants born from mothers known to have (any) hepatitis or human immunodeficiency virus;
  • \. Infants born from mothers with significant medical conditions during pregnancy that might interfere with the study or its outcome parameters or known to affect intra-uterine growth (e.g. placenta previa, pre-eclampsia, eclampsia, Type 1, 2 diabetes) as per clinical judgement of the Investigator;
  • \. Infants born from mothers, who did participate in any clinical study involving investigational products during pregnancy, and for infants in Breastfed reference group: mothers who are currently participating or intend to participate in any clinical study involving investigational products during lactation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Poliklinika Ginekologiczno-Położnicza Sp. z o.o. Sp. k.

Bialystok, 15-435, Poland

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 4, 2019

First Posted

July 10, 2019

Study Start

July 10, 2019

Primary Completion

December 3, 2021

Study Completion

December 3, 2021

Last Updated

December 17, 2021

Record last verified: 2021-12

Locations